Breakthrough SARS-CoV-2 infections in immune mediated disease patients undergoing B cell depleting therapy: A retrospective cohort analysis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35791921/
doi: 10.1002/art.42287. Online ahead of print. 1 Department of Rheumatic and Immunologic Diseases, Cleveland Clinic. 2 Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic. 3 Department of Dermatology, Cleveland Clinic. 4 Quantitative Health Sciences, Cleveland Clinic. doi: 10.1002/art.42287. Online ahead of print. 1 Department of Rheumatic and Immunologic Diseases, Cleveland Clinic.
Conclusions: IMIDs patients on BCDT regardless of vaccine status appear vulnerable to infection with SARS-CoV-2 and are frequently associated with severe outcomes. Outpatient use of anti-SARS-CoV-2 monoclonal antibody therapy appeared to be associated with enhanced clinical outcomes.